title: [3D conformal radiation therapy and hormonal therapy for localized prostate cancer: is age a limiting factor?].
abstract: No study on side effects had showed that conformal radiation therapy for prostate cancer is more harmful in patients older than 70 years to patients younger. The aim of this study was to evaluate acute and late toxicities of conformal radiotherapy, with high dose for localized prostate cancer in patients older than 70 years and compared to patients younger than 70 years. Between 1996 and 2009, 104 patients were treated with radiation therapy and hormonal therapy for localized cancer prostate. Median follow-up was 105 months (9-300). Acute (occurred at ≤ three months) and late side effects of 55 patients older than 70 years (median age: 75 [71-92]) were graded according to the CTCAE 3.0 criteria and compared to the younger population. Median dose to the prostate was 75.6 Gy (67-80) in both groups. There were no significant differences in acute and late side effects between age groups. For patients above 70 years, the incidence of grade II or higher acute and late side effects were respectively 27 and 22% for urologic symptoms and 13 and 16% for rectal symptoms. The frequency of grade III late symptoms was low and ranged between 0 and 6% for the evaluated symptoms, irrespective of age group. Older patients had a better biochemical recurrence-free survival than younger patients (86 versus 77% at four years, P=ns). High dose 3D conformal radiotherapy for localized prostate cancer was well tolerated in patients older than 70 years. Age is not a limiting factor for conformal radiation therapy and hormonotherapy for older patients.
authors.affiliation: Service d'urologie, hôpital La Conception, AP-HM, 147, boulevard Baille, 13385 Marseille cedex 5, France. alice.faure@ap-hm.fr
authors.forename: A
authors.initials: A
authors.lastname: Faure
authors.forename: T
authors.initials: T
authors.lastname: Negre
authors.forename: X
authors.initials: X
authors.lastname: Murraciole
authors.forename: E
authors.initials: E
authors.lastname: Jouve
authors.forename: R
authors.initials: R
authors.lastname: Sambuc
authors.forename: D
authors.initials: D
authors.lastname: Cowen
authors.forename: E
authors.initials: E
authors.lastname: Lechevallier
authors.forename: C
authors.initials: C
authors.lastname: Coulange
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000075202:Contraindications; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D020266:Radiotherapy, Conformal / Q000009:adverse effects* / Q000379:methods; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists